Therefore, we speculated that PD-1/PD-L1 plus lenvatinib would be recommended as a promising first-line treatment for advanced ICC patients who refuse or are intolerant to chemotherapy. Here, PDCD1 is linked to intrahepatic cholangiocarcinoma.